WS
CRSP icon

Wedbush Securities’s CRISPR Therapeutics CRSP Stock Holding History

Wedbush Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,138
Closed -$203K – 1218
2025
Q3 		$203K Buy
+3,138
New +$180K 0.01% 1072
2024
Q3 		– Sell
-5,677
Closed -$307K – 1133
2024
Q2 		$307K Buy
5,677
+366
+7% +$21.2K 0.01% 851
2024
Q1 		$362K Buy
5,311
+1,153
+28% +$82.5K 0.01% 780
2023
Q4 		$260K Buy
+4,158
New +$230K 0.01% 833
2023
Q3 		– Sell
-3,767
Closed -$211K – 1064
2023
Q2 		$211K Sell
3,767
-1,188
-24% -$67.4K 0.01% 909
2023
Q1 		$224K Buy
+4,955
New +$241K 0.01% 893
2022
Q4 		– Sell
-5,656
Closed -$370K – 1067
2022
Q3 		$370K Sell
5,656
-3,043
-35% -$221K 0.02% 629
2022
Q2 		$529K Hold
8,699
– – 0.03% 510
2022
Q1 		$546K Sell
8,699
-506
-5% -$31.8K 0.03% 540
2021
Q4 		$698K Buy
9,205
+910
+11% +$79.5K 0.03% 497
2021
Q3 		$928K Sell
8,295
-263
-3% -$33K 0.04% 379
2021
Q2 		$1.39M Sell
8,558
-101
-1% -$12.3K 0.07% 278
2021
Q1 		$1.05M Buy
+8,659
New +$1.31M 0.06% 314

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's CRSP Position: Q4 2025 in Review

Wedbush Securities sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,138 shares — an estimated $203K sold.

Wedbush Securities first reported a position in CRSP in Q1 2021 and held it in 13 quarters. The position peaked at $1.39M in Q2 2021. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Wedbush Securities reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wedbush Securities sold 3,138 CRISPR Therapeutics shares in Q4 2025, an estimated $203K.
  • Wedbush Securities first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 13 quarters.
  • Wedbush Securities's CRISPR Therapeutics position peaked at $1.39M in Q2 2021.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Wedbush Securities's 13F filing for Q4 2025, filed 12 Feb 2026.